Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1516 - Real-World Outcomes of Idelalisib in Relapsed/Refractory CLL Including High-Risk Patients and Post-BTKi/BCL2 Therapy: A Single-Center Experience from 2016 to 2025

    Primary Author / Presenter(s)

  • Peter Turcsanyi, MD, PhD

    clinician, MD.
    Department of Hemato-oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc
    Olomouc, Olomoucky kraj, Czech Republic

    • Co-Author(s)

  • RU

    Renata Urbanová, MD, PhD

    Assistant
    Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc
    Olomouc, Czech Republic

  • AP

    Anna Petráčková, PhD

    Institute of Immunology Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc
    Olomouc, Czech Republic

  • ZK

    Zuzana Kubová, MD

    physician
    Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc
    Olomouc, Olomoucky kraj, Czech Republic

  • TP

    Tomas Papajik, MD

    Prof, MD., head of institution
    Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc
    Olomouc, Olomoucky kraj, Czech Republic

  • EK

    Eva Kriegová, Doc., Ing

    Institute of Immunology Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc
    Olomouc, Olomoucky kraj, Czech Republic